Construction and analysis of competing endogenous RNA network of MCF‑7 breast cancer cells based on the inhibitory effect of 6‑thioguanine on cell proliferation

Li,Hao; An,Xinglan; Li,Qi; Yu,Hao; Li,Ziyi

doi:10.3892/ol.2020.12365

Construction and analysis of competing endogenous RNA network of MCF‑7 breast cancer cells based on the inhibitory effect of 6‑thioguanine on cell proliferation

Authors:
- Hao Li
- Xinglan An
- Qi Li
- Hao Yu
- Ziyi Li
View Affiliations

Affiliations: Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China, College of Animal Sciences, Jilin University, Changchun, Jilin 130062, P.R. China
Published online on: December 10, 2020 https://doi.org/10.3892/ol.2020.12365
Article Number: 104
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous research has proven that 6‑thioguanine (6‑TG) inhibits the growth of MCF‑7 breast cancer cells. Accumulating evidence indicates that long non‑coding (lnc)RNAs are involved in the development of various cancer types as competitive endogenous (ce)RNA molecules. The present study was conducted to investigate the regulatory mechanism underlying the function of lncRNAs as ceRNA molecules in MCF‑7 cells and to identify more effective prognostic biomarkers for breast cancer treatment. The expression profiles of lncRNAs in untreated MCF‑7 cells and 6‑TG‑treated MCF‑7 cells were compared by RNA‑seq. The regulatory associations among lncRNAs, micro (mi)RNAs and mRNAs were analyzed and verified by the TargetScan, miRDB and miRTarBas databases. The ceRNA networks were constructed by Cytoscape. The expression levels of two lncRNAs and two miRNAs in the ceRNA network were measured by reverse transcription‑quantitative PCR. The OncoLnc and Kaplan‑Meier plotter network databases were utilized to determine the effects of lncRNA and miRNA expression on the survival of patients with breast cancer. A ceRNA network was constructed for MCF‑7 breast cancer cells treated with 6‑TG, and this network may provide valuable information for further research elucidating the molecular mechanism underlying the effects of 6‑TG on breast cancer. Moreover, LINC00324, MIR22HG, miR‑370‑3p and miR‑424‑5p were identified as potential prognostic and therapeutic biomarkers for breast cancer.

View Figures

View References

1	Fahad Ullah M: Breast cancer: Current perspectives on the disease status. Adv Exp Med Biol. 1152:51–64. 2019. View Article : Google Scholar
2	Jeong SB, Im JH, Yoon JH, Bui QT, Lim SC, Song JM, Shim Y, Yun J, Hong J and Kang KW: Essential role of polo-like kinase 1 (Plk1) oncogene in tumor growth and metastasis of tamoxifen-resistant breast cancer. Mol Cancer Ther. 17:825–837. 2018. View Article : Google Scholar : PubMed/NCBI
3	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar
4	Geng C, Tang P, Zhang Y and Gao W: Hyponatremia induced by low-dose cyclophosphamide in two patients with breast cancer. Breast J. 20:442–443. 2014. View Article : Google Scholar : PubMed/NCBI
5	Natori A, Ethier JL, Amir E and Cescon DW: Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. Eur J Cancer. 77:40–47. 2017. View Article : Google Scholar : PubMed/NCBI
6	Shafei A, El-Bakly W, Sobhy A, Wagdy O, Reda A, Aboelenin O, Marzouk A, El Habak K, Mostafa R, Ali MA and Ellithy M: A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother. 95:1209–1218. 2017. View Article : Google Scholar : PubMed/NCBI
7	Li C, Liang Y, Cao J, Zhang N, Wei X, Tu M, Xu F and Xu Y: The delivery of a Wnt pathway inhibitor toward CSCs requires stable liposome encapsulation and delayed drug release in tumor tissues. Mol Ther. 27:1558–1567. 2019. View Article : Google Scholar : PubMed/NCBI
8	Karran P and Attard N: Thiopurines in current medical practice: Molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer. 8:24–36. 2008. View Article : Google Scholar : PubMed/NCBI
9	Munshi PN, Lubin M and Bertino JR: 6-thioguanine: A drug with unrealized potential for cancer therapy. Oncologist. 19:760–765. 2014. View Article : Google Scholar : PubMed/NCBI
10	Dubinsky MC, Feldman EJ, Abreu MT, Targan SR and Vasiliauskas EA: Thioguanine: A potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol. 98:1058–1063. 2003. View Article : Google Scholar : PubMed/NCBI
11	Kim I, Choi YS, Song JH, Choi EA, Park S, Lee EJ, Rhee JK, Kim SC and Chang S: A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer cells. Mol Oncol. 12:1526–1539. 2018. View Article : Google Scholar : PubMed/NCBI
12	Li H, An X, Zhang D, Li Q, Zhang N, Yu H and Li Z: Transcriptomics analysis of the tumor-inhibitory pathways of 6-Thioguanine in MCF-7 cells via silencing DNMT1 activity. Onco Targets Ther. 13:1211–1223. 2020. View Article : Google Scholar : PubMed/NCBI
13	Anastasiadou E, Jacob LS and Slack FJ: Non-coding RNA networks in cancer. Nat Rev Cancer. 18:5–18. 2018. View Article : Google Scholar : PubMed/NCBI
14	de Almeida RA, Fraczek MG, Parker S, Delneri D and O'Keefe RT: Non-coding RNAs and disease: The classical ncRNAs make a comeback. Biochem Soc Trans. 44:1073–1078. 2016. View Article : Google Scholar
15	Dong Z, Zhang A, Liu S, Lu F, Guo Y, Zhang G, Xu F, Shi Y, Shen S, Liang J and Guo W: Aberrant methylation-mediated silencing of lncRNA MEG3 Functions as a ceRNA in esophageal cancer. Mol Cancer Res. 15:800–810. 2017. View Article : Google Scholar : PubMed/NCBI
16	Conte F, Fiscon G, Chiara M, Colombo T, Farina L and Paci P: Role of the long non-coding RNA PVT1 in the dysregulation of the ceRNA-ceRNA network in human breast cancer. PLoS One. 12:e01716612017. View Article : Google Scholar : PubMed/NCBI
17	Wang H, Huo X, Yang XR, He J, Cheng L, Wang N, Deng X, Jin H, Wang N, Wang C, et al: STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer. 16:1362017. View Article : Google Scholar : PubMed/NCBI
18	Li H, Wang X, Wen C, Huo Z, Wang W, Zhan Q, Cheng D, Chen H, Deng X, Peng C and Shen B: Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. Mol Cancer. 16:1692017. View Article : Google Scholar : PubMed/NCBI
19	Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP: A ceRNA hypothesis: The rosetta stone of a hidden RNA language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
20	Xu J, Li Y, Lu J, Pan T, Ding N, Wang Z, Shao T, Zhang J, Wang L and Li X: The mRNA related ceRNA-ceRNA landscape and significance across 20 major cancer types. Nucleic Acids Res. 43:8169–8182. 2015. View Article : Google Scholar : PubMed/NCBI
21	Qi X, Zhang DH, Wu N, Xiao JH, Wang X and Ma W: ceRNA in cancer: Possible functions and clinical implications. J Med Genet. 52:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
22	Wang H, Niu L, Jiang S, Zhai J, Wang P, Kong F and Jin X: Comprehensive analysis of aberrantly expressed profiles of lncRNAs and miRNAs with associated ceRNA network in muscle-invasive bladder cancer. Oncotarget. 7:86174–86185. 2016. View Article : Google Scholar : PubMed/NCBI
23	Zheng L, Xiang C, Li X, Guo Q, Gao L, Ni H, Xia Y and Xi T: STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling. J Hematol Oncol. 11:722018. View Article : Google Scholar : PubMed/NCBI
24	Fan CN, Ma L and Liu N: Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer. J Transl Med. 16:2642018. View Article : Google Scholar : PubMed/NCBI
25	Karreth FA and Pandolfi PP: ceRNA cross-talk in cancer: When ce-bling rivalries go awry. Cancer Discov. 3:1113–1121. 2013. View Article : Google Scholar : PubMed/NCBI
26	Gao C, Li H, Zhuang J, Zhang H, Wang K, Yang J, Liu C, Liu L, Zhou C and Sun C: The construction and analysis of ceRNA networks in invasive breast cancer: A study based on the cancer genome atlas. Cancer Manag Res. 11:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
27	Sui J, Li YH, Zhang YQ, Li CY, Shen X, Yao WZ, Peng H, Hong WW, Yin LH, Pu YP and Liang GY: Integrated analysis of long non-coding RNAassociated ceRNA network reveals potential lncRNA biomarkers in human lung adenocarcinoma. Int J Oncol. 49:2023–2036. 2016. View Article : Google Scholar : PubMed/NCBI
28	Xue WH, Fan ZR, Li LF, Lu JL, Ma BJ, Kan QC and Zhao J: Construction of an oesophageal cancer-specific ceRNA network based on miRNA, lncRNA, and mRNA expression data. World J Gastroenterol. 24:23–34. 2018. View Article : Google Scholar : PubMed/NCBI
29	Chu A, Liu J, Yuan Y and Gong Y: Comprehensive analysis of aberrantly expressed ceRNA network in gastric cancer with and without H. pylori infection. J Cancer. 10:853–863. 2019. View Article : Google Scholar : PubMed/NCBI
30	Jia X, Shi Y, Zhu Y, Meng W, He L, Jia Y and Tong Z: Integrated analysis of mRNA-miRNA-lncRNA ceRNA network in human HR+/Her-2-breast cancer and triple negative breast cancer. J Comput Biol. 27:1055–1066. 2020. View Article : Google Scholar : PubMed/NCBI
31	Yao Y, Zhang T, Qi L, Zhou C, Wei J, Feng F, Liu R and Sun C: Integrated analysis of co-expression and ceRNA network identifies five lncRNAs as prognostic markers for breast cancer. J Cell Mol Med. 23:8410–8419. 2019. View Article : Google Scholar : PubMed/NCBI
32	Li XL, Subramanian M, Jones MF, Chaudhary R, Singh DK, Zong X, Gryder B, Sindri S, Mo M, Schetter A, et al: Long noncoding RNA PURPL suppresses basal p53 levels and promotes tumorigenicity in colorectal cancer. Cell Rep. 20:2408–2423. 2017. View Article : Google Scholar : PubMed/NCBI
33	Fu X, Wang Y, Wu G, Zhang W, Xu S and Wang W: Long noncoding RNA PURPL promotes cell proliferation in liver cancer by regulating p53. Mol Med Rep. 19:4998–5006. 2019.PubMed/NCBI
34	Pan ZH, Guo XQ, Shan J and Luo SX: LINC00324 exerts tumor-promoting functions in lung adenocarcinoma via targeting miR-615-5p/AKT1 axis. Eur Rev Med Pharmacol Sci. 22:8333–8342. 2018.PubMed/NCBI
35	Zou Z, Ma T, He X, Zhou J, Ma H, Xie M, Liu Y, Lu D, Di S and Zhang Z: Long intergenic non-coding RNA 00324 promotes gastric cancer cell proliferation via binding with HuR and stabilizing FAM83B expression. Cell Death Dis. 9:7172018. View Article : Google Scholar : PubMed/NCBI
36	Ni X, Xie JK, Wang H and Song HR: Knockdown of long non-coding RNA LINC00324 inhibits proliferation, migration and invasion of colorectal cancer cell via targeting miR-214-3p. Eur Rev Med Pharmacol Sci. 23:10740–10750. 2019.PubMed/NCBI
37	Zhang DY, Zou XJ, Cao CH, Zhang T, Lei L, Qi XL, Liu L and Wu DH: Identification and functional characterization of long non-coding RNA MIR22HG as a tumor suppressor for hepatocellular carcinoma. Theranostics. 8:3751–3765. 2018. View Article : Google Scholar : PubMed/NCBI
38	Qin L, Luo JZ, Tang XL and Han CG: Identification of long noncoding RNA MIR22HG as a novel biomarker in thyroid cancer. Pathol Oncol Res. 25:703–710. 2019. View Article : Google Scholar : PubMed/NCBI
39	Su W, Feng S, Chen X, Yang X, Mao R, Guo C, Wang Z, Thomas DG, Lin J, Reddy RM, et al: Silencing of long noncoding RNA MIR22HG triggers cell survival/death signaling via oncogenes YBX1, MET, and p21 in lung cancer. Cancer Res. 78:3207–3219. 2018.PubMed/NCBI
40	Wu Y, Zhou Y, Huan L, Xu L, Shen M, Huang S and Liang L: LncRNA MIR22HG inhibits growth, migration and invasion through regulating the miR-10a-5p/NCOR2 axis in hepatocellular carcinoma cells. Cancer Sci. 110:973–984. 2019. View Article : Google Scholar : PubMed/NCBI
41	Zhang J, Liu H, Hou L, Wang G, Zhang R, Huang Y, Chen X and Zhu J: Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. Mol Cancer. 16:1512017. View Article : Google Scholar : PubMed/NCBI
42	Liu X, Fu Y, Zhang G, Zhang D, Liang N, Li F, Li C, Sui C, Jiang J, Lu H, et al: miR-424-5p promotes anoikis resistance and lung metastasis by inactivating Hippo signaling in thyroid cancer. Mol Ther Oncolytics. 15:248–260. 2019. View Article : Google Scholar : PubMed/NCBI
43	Dai W, Zhou J, Wang H, Zhang M, Yang X and Song W: miR-424-5p promotes the proliferation and metastasis of colorectal cancer by directly targeting SCN4B. Pathol Res Pract. 216:1527312020. View Article : Google Scholar : PubMed/NCBI
44	Hou WZ, Chen XL, Wu W and Hang CH: MicroRNA-370-3p inhibits human vascular smooth muscle cell proliferation via targeting KDR/AKT signaling pathway in cerebral aneurysm. Eur Rev Med Pharmacol Sci. 21:1080–1087. 2017.PubMed/NCBI
45	Lyu L, Yao J, Wang M, Zheng Y, Xu P, Wang S, Zhang D, Deng Y, Wu Y, Yang S, et al: Overexpressed pseudogene HLA-DPB2 promotes tumor immune infiltrates by regulating HLA-DPB1 and indicates a better prognosis in breast cancer. Front Oncol. 10:12452020. View Article : Google Scholar : PubMed/NCBI
46	Salvador JM, Brown-Clay JD and Fornace AJ Jr: Gadd45 in stress signaling, cell cycle control, and apoptosis. Adv Exp Med Biol. 793:1–19. 2013. View Article : Google Scholar : PubMed/NCBI
47	Li T, Xu L, Teng J, Ma Y, Liu W, Wang Y, Chi X, Shao S, Dong Y, Zhan Q and Liu X: GADD45G Interacts with E-cadherin to suppress the migration and invasion of esophageal squamous cell carcinoma. Dig Dis Sci. 65:1032–1041. 2020. View Article : Google Scholar : PubMed/NCBI
48	Guo W, Zhu T, Dong Z, Cui L, Zhang M and Kuang G: Decreased expression and aberrant methylation of Gadd45G is associated with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Clin Exp Metastasis. 30:977–992. 2013. View Article : Google Scholar : PubMed/NCBI
49	Misiewicz-Krzeminska I, Sarasquete ME, Vicente-Dueñas C, Krzeminski P, Wiktorska K, Corchete LA, Quwaider D, Rojas EA, Corral R, Martín AA, et al: Post-transcriptional modifications contribute to the upregulation of cyclin D2 in multiple myeloma. Clin Cancer Res. 22:207–217. 2016. View Article : Google Scholar : PubMed/NCBI